HbA@c ( baseline : dapagliflozin @ % -LSB- @ mmol/mol -RSB- ; placebo @ % -LSB- @ mmol/mol -RSB- ) and fasting plasma glucose ( baseline : dapagliflozin @ mg/dL -LSB- @ mmol/L -RSB- ; placebo @ mg/dL -LSB- @ mmol/L -RSB- ) significantly improved from baseline with dapagliflozin ( placebo-subtracted change -@ % -LSB- -@ mmol/mol -RSB- , P < @ ; -@ mg/dL -LSB- -@ mmol/L -RSB- , P < @ , respectively ) .